Drug Information Consult Response Note

Note Type: Drug Information Consult Response

Date/Time: [Date and time note authored]

Author: [Name, credentials, service]

Consult Type: [patient-specific / non-patient-specific]

(Use only organization-approved abbreviations; avoid error-prone medication abbreviations. Use leading zeros for values less than 1, avoid trailing zeros in doses, and always specify units and routes. Maintain objective, nonjudgmental language. Clearly distinguish what was asked, what was found in the chart, what was found in the literature, and what is recommended. Omit optional sections entirely if not applicable. For required elements that are unknown, document as "Unknown—not provided" and note the impact on certainty.)

Request Details

Requester: [Name, role, service/team, contact method if provided]

Request Received: [Date and time] | Urgency: [STAT / urgent / routine] (Include reason if urgent or STAT)

Question Category: [dosing adjustment / drug interaction / adverse effect / allergy or cross-reactivity / pregnancy or lactation / compatibility or stability / therapeutic alternative / off-label use / toxicology / other]

Clinical Intent: [Decision or action pending based on this response]

Restated Question

[Clarified primary question in one sentence, including scope boundaries]

• [Subquestion 1] (Include only if multiple distinct subquestions exist)
• [Subquestion 2]

Critical Information Gaps: [Missing data that prevents safe or complete answer, with interim guidance provided] (Include only if critical data are missing; otherwise omit this line)

Patient Context

(Include this section only for patient-specific consults; omit entirely for non-patient-specific questions.)

Summary: [Age, key comorbidities, clinical scenario and indication in 1–2 lines]

Allergies: [Relevant allergies with reaction type and severity]

Pertinent Medications: [Only medications relevant to the question, with dose and frequency]

Renal: [CrCl or eGFR with units, timestamp, and calculation method if known]

Hepatic: [Pertinent hepatic function results with units and timestamp]

Cardiac/QTc: [Most recent QTc with timestamp] (Include only if relevant to question)

Drug Levels: [Therapeutic drug monitoring values with timestamps] (Include only if relevant to question)

Patient-Specific Factors: [Pregnancy or lactation status, weight, organ support such as CRRT or ECMO, immunocompromised status, other relevant factors]

(If an essential element is unknown, document: "Unknown—unable to fully assess without [specific data needed].")

Recommendation Summary

Recommendation: [One-sentence actionable conclusion]

• Key Rationale: [Evidence-based reason tied to the question and patient context if applicable]
• [Additional rationale point]

• Safety/Monitoring: [Specific safety flag or monitoring need with action threshold]
• [Additional monitoring parameter]

Therapeutic Alternatives: [Preferred option, then alternatives in order of preference] (Include only if alternatives exist)

Evidence Review

Resources Consulted: [Tertiary references, product labeling, guidelines, primary literature as applicable]

• Key Findings: [Efficacy, safety, dosing, or comparative data relevant to the question]
• Quality/Limitations: [Study types, applicability, limitations]
• Regulatory Status: [on-label / off-label]
• Conflicting Evidence: [Description of conflict and how it was weighed] (Include only if evidence conflicts)
• Evidence Gaps: [Unanswered questions or areas with insufficient data] (Include only if gaps exist)

(For straightforward questions, a concise statement is acceptable, e.g., "Per manufacturer labeling" or "Per [guideline name].")

Risk/Benefit Analysis

(Include for patient-specific consults involving meaningful clinical decision-making; omit for straightforward or non-patient-specific questions.)

• Expected Benefit: [Clinical benefit and anticipated timeframe]
• Key Risks: [Toxicity, interactions, contraindications, patient-specific risk factors]
• Alternatives: [Viable alternatives with brief rationale] (Include if recommended option carries substantial risk or is unavailable)
• Monitoring/Mitigation: [Specific monitoring with timing and action thresholds]
• Operational Considerations: [Formulary status, availability, route feasibility, administration logistics] (Include only if relevant)
• Source Data for Adjustments: [Renal or hepatic function values and timestamps used for dosing calculations]

Detailed Plan

• Medication: [Drug name spelled out], [dose with units], [route], [frequency], [duration]
• Adjustments: [Renal or hepatic adjustment thresholds and adjusted dosing]
• Administration: [Infusion rate, timing relative to food or interacting agents, preparation notes]
• Monitoring: [Parameter], [frequency], [action threshold and response]
• Contingencies: [Instructions for deterioration, adverse effects, or therapeutic failure]
• Follow-up: [Responsible party and timeline for reassessment]

Communication

Contact: [Name and role] | Method: [phone / pager / secure message / in-person] | Date/Time: [Date and time of communication]

Outcome: [acknowledged / accepted / declined / pending] (If unable to reach requester, document attempts and backup notification plan; for emergent safety issues, document escalation pathway used.)

References

• [Reference 1]
• [Reference 2]
• [Additional references as needed, 2–6 total]

Electronically signed by: [Name, credentials] | [Date/Time] | [Service/Department]